STOCK TITAN

Rallybio Corporation - RLYB STOCK NEWS

Welcome to our dedicated page for Rallybio Corporation news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio Corporation stock.

Rallybio Corporation Common Stock (Symbol: RLYB) is a clinical-stage biotechnology company founded in January 2018 and based in Farmington, CT at the University of Connecticut’s Technology Incubation Program. The company is dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Rallybio’s founders and team members boast a notable track record in pharmaceutical research and development, effectively leveraging their expertise to pursue promising drug candidates.

Rallybio’s core focus lies in developing treatments that target severe and often devastating diseases. Among its key projects is a program aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare and potentially life-threatening condition that can cause uncontrolled bleeding in fetuses and newborns. This program exemplifies Rallybio’s commitment to tackling unmet medical needs through innovative solutions.

The company’s approach involves working on drug candidates with strong biological rationales, utilizing well-validated therapeutic modalities such as small molecules, engineered proteins, and antibodies. By prioritizing robust clinical and commercial filters, Rallybio ensures that only the most promising assets are advanced through the development pipeline.

Recent achievements and ongoing projects highlight Rallybio’s progress and potential in the biotechnology sector. The company continues to build strategic partnerships and collaborations, enhancing its capabilities and resources for drug development. Financially, Rallybio remains focused on securing the necessary funding to support its ambitious research and development goals.

For investors and stakeholders, Rallybio Corporation represents a forward-thinking entity with a clear mission to improve patient outcomes through groundbreaking therapies. The company’s strategic location within a renowned technology incubation program underscores its innovative spirit and commitment to cutting-edge research.

Rhea-AI Summary
Rallybio partners with Johnson & Johnson to develop therapies for FNAIT, receives $6.6 million investment. RLYB212 aims to prevent FNAIT in pregnant individuals. Phase 2 study planned for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.82%
Tags
none
-
Rhea-AI Summary
Rallybio (RLYB) to present data on Fetal and Neonatal Alloimmune Thrombocytopenia at AMCP 2024 Annual Meeting. The company is developing RLYB212 to prevent FNAIT in pregnant mothers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
-
Rhea-AI Summary
Rallybio Corporation (RLYB) receives Protocol Assistance Feedback from European Medicines Agency on Phase 2 Study for RLYB212, plans to proceed with Clinical Trial Application Process in Europe. Phase 2 Dose Confirmation Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT set to start in 2H 2024. The company has $109.9 million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2023, providing financial runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announced that its CEO will participate in a panel discussion on Orphan Bone & Neuromuscular Diseases at the TD Cowen 44th Annual Health Care Conference. The live webcast can be accessed on Rallybio's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
conferences
-
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announces the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. The company expects to extend its cash runway into mid-2026. RLYB212 is a monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia, while RLYB116 is a C5 inhibitor for patients with complement-mediated diseases. The workforce reduction will result in approximately $3.3 million in charges, but the company's cash, cash equivalents, and marketable securities of $109.9 million as of December 31, 2023, are expected to fund its operating plan into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24%
Tags
none
-
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) provides updates on recent accomplishments and expected 2024 milestones, including the initiation of a Phase 2 study for RLYB212, discussions with the European Medicines Agency, and extended cash runway into 3Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, showing a mean reduction of greater than 93% in free C5 with low volume once-a-week subcutaneous dosing. The data supports the study of RLYB116 as a differentiated therapeutic for the treatment of Generalized Myasthenia Gravis. The company also announced an extension of runway to 3Q 2025 as part of portfolio prioritization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
-
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) presented details from the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study at the 65th American Society of Hematology (ASH) Annual Meeting. The study aims to determine the frequency of expectant mothers of diverse races and ethnicities at higher FNAIT risk, with a prospective goal of screening up to 30,000 expectant mothers and an estimated 7,600 women screened by the end of 2023. The study is designed to provide a contemporary control dataset to support a future registrational trial in pregnant women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rallybio Corporation (RLYB) released preliminary data from the Phase 1 safety and pharmacokinetics study for RLYB212, an anti-HPA-1a monoclonal antibody for fetal and neonatal alloimmune thrombocytopenia prevention. The data supports a once monthly dosing regimen for the planned Phase 2 study. The toxicology package to support Phase 2 and Phase 3 studies is complete, including maternal-fetal toxicology. Phase 2 study expected to commence in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) reported financial results and provided an update on recent program and corporate developments. The company completed the multiple dose cohort of the Phase 1 study for RLYB212 and is on track for a 4Q 2023 data release. Initial data from the RLYB116 Phase 1 study is also on track for a 4Q 2023 release. The company has $121.4 million in cash, cash equivalents, and marketable securities as of September 30, 2023, providing runway into 1Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags

FAQ

What is the current stock price of Rallybio Corporation (RLYB)?

The current stock price of Rallybio Corporation (RLYB) is $0.95 as of December 20, 2024.

What is the market cap of Rallybio Corporation (RLYB)?

The market cap of Rallybio Corporation (RLYB) is approximately 41.5M.

What does Rallybio Corporation do?

Rallybio Corporation is a biotechnology company dedicated to developing life-transforming therapies for severe and rare disorders.

When was Rallybio Corporation founded?

Rallybio Corporation was founded in January 2018.

Where is Rallybio Corporation located?

Rallybio Corporation is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program.

What is Rallybio's key research focus?

Rallybio focuses on developing treatments for severe and rare diseases, including a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

What are some of the therapeutic modalities used by Rallybio?

Rallybio uses well-validated therapeutic modalities such as small molecules, engineered proteins, and antibodies.

Who founded Rallybio Corporation?

Rallybio was founded by seasoned leaders from the biopharma industry with extensive experience in research, development, and finance.

How does Rallybio select its drug candidates?

Rallybio uses a series of robust clinical and commercial filters to evaluate and select highly promising drug candidates.

What makes Rallybio's approach unique?

Rallybio combines a strong biological rationale with well-validated therapeutic modalities to address severe and rare diseases.

Is Rallybio a publicly traded company?

Rallybio Corporation is a private, early-stage biotechnology company.

What recent achievements has Rallybio made?

Rallybio has made significant progress in its research and development programs, established strategic partnerships, and secured funding to support its goals.

Rallybio Corporation

Nasdaq:RLYB

RLYB Rankings

RLYB Stock Data

41.49M
36.75M
4.06%
76.31%
0.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN